T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Commentary|Articles|May 5, 2026
Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Kirsty Mackay
Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.
Advertisement
Advertisement
As we gear up for the
Related to this article
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1–positive, metastatic triple-negative breast cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement